Sign in

PBM on Nasdaq

PSYENCE BIOMEDICAL LTD.

PSYENCE BIOMEDICAL LTD. is a Canadian pharmaceutical preparations company based in Toronto.1 Its shares trade on Nasdaq under the symbol PBM.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerPBM on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersA61
  • Incorporated inOntario, Canada2
  • Business address121 Richmond Street West Penthouse, Suite 1300, Toronto2
  • Filer categoryNon-accelerated filer, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

(“ SPAC ”). The agreement aimed to create a public company leveraging natural psilocybin for palliative care treatment.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Net income4$1.0M in 2025
-$60.0M-$40.0M-$20.0M0$20.0M2023: -$3.2M-$3.2M20232024: -$51.2M-$51.2M2024+1496%2025: $1.0M$1.0M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2026-03-312025-03-312024-03-31
Sales and marketing$218.5K$483.5K$80.6K
Research and development$1.5M$342.2K$954.6K
General and administrative$892.3K$1.2M$557.9K
Professional and consulting fees$3.7M$1.6M$1.2M
Loss before other items-$6.2M-$3.7M-$2.8M
Other income$292.2K$879.3K
Other expense-$1.5M
Depreciation-$5.3K-$4.3K-$240
Interest income$263.4K$95.8K$2.1K
Interest expense-$9.5K-$9.3K-$52.9K
Foreign exchange loss-$1.1K-$7.3K-$2.7K
Listing expense-$41.5M
Transaction expense-$2.5M
Gain on debt settlement$281.5K
Fair value gain/(loss) on convertible note$3.4M-$5.2M
Fair value gain/(loss) on warrant liability-$15.4K$694.5K-$306.2K
Fair value gain/(loss) on promissory notes$705.6K-$108.3K
Fair value loss on warrant exchange-$185.1K
Fair value gain on investment in Psyence Labs Ltd$427.0K$23.0K
Fair value loss on digital assets-$110.2K
Share of losses from Associate-$45.2K
NET INCOME/(LOSS)-$6.9M$1.0M-$51.2M
Foreign exchange gain/(loss) on translation$45.0K-$9.9K$3.7K
Other comprehensive income$192.0K
TOTAL COMPREHENSIVE INCOME/(LOSS)-$6.9M$1.0M-$51.0M
Income/(Loss) per share - basic (in Dollars per share)-$12.56$32.76-$29,214.06
Income/(Loss) per share - diluted (in Dollars per share)-$12.56$32.76-$29,214.06
Weighted average number of outstanding shares - basic (in Shares)552.3K shares30.9K shares1.7K shares
Weighted average number of outstanding shares - diluted (in Shares)552.3K shares30.9K shares1.7K shares

Compare PSYENCE BIOMEDICAL LTD. with another company

Corporate structure

PSYENCE BIOMEDICAL LTD. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of PSYENCE BIOMEDICAL LTD.

  • Psyence Labs Ltd Filed SCHEDULE 13D/A on PSYENCE BIOMEDICAL LTD., latest Oct 15, 2026 (2 filings since Jun 3, 2026)
  • AdvisorShares Trust Filed SCHEDULE 13G on PSYENCE BIOMEDICAL LTD., latest Oct 5, 2026 (3 filings since Nov 12, 2024)
  • Jeffrey David Weiner Filed SCHEDULE 13G/A on PSYENCE BIOMEDICAL LTD., latest Jun 10, 2026 (2 filings since Feb 19, 2026)
  • Kaos Capital Ltd Filed SCHEDULE 13D/A on PSYENCE BIOMEDICAL LTD., latest Jan 13, 2026 (2 filings since Dec 10, 2025)
  • Harraden Circle Investments, LLC Filed SCHEDULE 13G/A on PSYENCE BIOMEDICAL LTD., latest May 15, 2025 (7 filings since Feb 5, 2024)
  • Hudson Bay Capital Management LP Filed SCHEDULE 13G/A on PSYENCE BIOMEDICAL LTD., latest May 14, 2025 (3 filings since Feb 10, 2025)
  • Psyence Group Inc. Filed SCHEDULE 13D/A on PSYENCE BIOMEDICAL LTD., latest May 12, 2025 (3 filings since Feb 5, 2024)
  • White Lion Capital LLC Filed SC 13G on PSYENCE BIOMEDICAL LTD., latest Dec 13, 2024
  • PSYENCE BIOMEDICAL LTD. A6

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PSYENCE BIOMEDICAL LTD. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$11.1K4 Mar 31, 2025$5.5K4 Mar 31, 2024+102.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.1M4 Mar 31, 2025$733.2K4 Mar 31, 2024+736.8%

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chairman of the Board and Strategic Business Development OfficerJody Aufrichtig named Jan 7, 20257
  • Executive Officer, DirectorNeil Maresky named Jan 7, 20257
  • Chief Financial officerWarwick Corden-Lloyd named Jan 7, 20257
  • DirectorBull Christopher named Jan 7, 20257
  • DirectorDr. Seth Feuerstein named Jan 7, 20257
  • DirectorMarc Balkin named Jan 7, 20257

Filings

169 filings to the SEC since October 2021: 5 annual reports, 23 large holders, 1 private raises, 140 other. The latest 20:

  1. Oct 15, 2026SCHEDULE 13D/A EDGAR
  2. Oct 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Oct 5, 2026SCHEDULE 13G EDGAR
  4. Sep 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Sep 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Sep 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Sep 1, 2026EFFECT EDGAR
  8. Aug 26, 2026S-8 REGISTRATION STATEMENT EDGAR
  9. Aug 26, 2026F-3 REGISTRATION STATEMENT EDGAR
  10. Aug 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  11. Jun 22, 202620-F ANNUAL REPORT EDGAR
  12. Jun 10, 2026SCHEDULE 13G/A EDGAR
  13. Jun 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Jun 3, 2026SCHEDULE 13D EDGAR
  15. Apr 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Apr 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Apr 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Apr 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  19. Mar 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. Feb 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR

The 169 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 27, 2024Raised $2 million in a private offering of equity Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Parallel Advisors, LLC151,250$574.8K0.0%No change
AdvisorShares Investments LLC122,184$373.9K0.0%New
Morgan Stanley37,804$115.7K0.0%New
Jane Street Group, LLC30,431$93.1K0.0%New
XTX Topco Ltd15,094$46.2K0.0%New
Citadel Advisors LLC11,693$35.8K0.0%New
Stonehage Fleming Financial Services Holdings Ltd89$2720.0%No change
UBS Group AG60$1840.0%New
Caitlin John, LLC35$1070.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How PSYENCE BIOMEDICAL LTD. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPSYENCE BIOMEDICAL LTD.1
  • CIK0001985062
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company3
  • Incorporated inOntario, Canada3
  • Fiscal year endsMarch 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address121 Richmond Street West Penthouse, Suite 1300, Toronto, Ontario, Canada1
  • Phone277446041711
  • Shares outstanding2,293,277 shares as of Mar 31, 20263
  • AuditorMNP LLP, Toronto, Canada PCAOB ID 1930; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceAug 1, 20231
  • Filings169 in all: 6-K (60), CORRESP (15), UPLOAD (13), 424B3 (10), EFFECT (10), F-1 (6), SCHEDULE 13G/A (6), F-1/A (5)1
    All 27 form types

    F-4/A (5), 20-F (4), SC 13G/A (4), SCHEDULE 13D/A (4), 425 (3), F-3 (3), S-8 (3), SC 13G (3), SCHEDULE 13G (3), SCHEDULE 13D (2), SEC STAFF LETTER (2), 20-F/A (1), 6-K/A (1), 8-A12B (1), CERT (1), D (1), F-4 (1), POS AM (1), SC 13D (1)

  • Latest filingsAnnual report (20-F) Jun 22, 2026

Securities registered for trading

ClassSymbolExchange
Common shares, without par valuePBMNasdaq
Warrants, each exercisable to purchase one Common Share at an exercise price of $42,963.28 per sharePBMWWNasdaq

From the cover page of the 20-F filed Jun 22, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15